4.4 Review

Effects of anti-tumor necrosis factor a agents on bone

Journal

CURRENT OPINION IN RHEUMATOLOGY
Volume 24, Issue 5, Pages 576-585

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOR.0b013e328356d212

Keywords

anti-TNF; bone loss; rheumatoid arthritis; spondyloarthropaties

Categories

Funding

  1. NIH [P60AR56116]
  2. Vanderbilt Orthopaedic Institute Pilot Grant
  3. Vanderbilt Physician Scientist Development Award

Ask authors/readers for more resources

Purpose of review Tumor necrosis factor (TNF) inhibitors are effective for achieving disease control in several inflammatory diseases. Although anti-TNF agents can inhibit bone loss in vitro, their role in the prevention of clinically relevant outcomes such as osteoporosis and fractures has not been clearly established. Recent findings There are many studies of the effects of TNF inhibitors on markers of bone turnover; however, few have measured bone mineral density (BMD) or fractures. Most of these studies have small sample sizes and a minority had a placebo control group. Overall these studies suggest that the antiresorptive effects of anti-TNF therapy are related to control of disease activity. Summary The antiresorptive effects of TNF inhibitors are likely related to their anti-inflammatory properties. Studies to date have not demonstrated any advantages of TNF inhibitors over traditional nonbiologic therapies in the prevention of bone loss and fractures.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available